about
Outer membrane vesicles as platform vaccine technologyNaturally occurring lipid A mutants in neisseria meningitidis from patients with invasive meningococcal disease are associated with reduced coagulopathyDissemination of lipid A deacylases (pagL) among gram-negative bacteria: identification of active-site histidine and serine residuesCrystal structure and catalytic mechanism of the LPS 3-O-deacylase PagL from Pseudomonas aeruginosaCoincorporation of LpxL1 and PagL mutant lipopolysaccharides into liposomes with Neisseria meningitidis opacity protein: influence on endotoxic and adjuvant activityDifferential effect of TLR2 and TLR4 on the immune response after immunization with a vaccine against Neisseria meningitidis or Bordetella pertussis.The structure of Neisseria meningitidis lipid A determines outcome in experimental meningococcal disease.LOS oligosaccharide modification enhances dendritic cell responses to meningococcal native outer membrane vesicles expressing a non-toxic lipid APrevalence and clinical course in invasive infections with meningococcal endotoxin variants.Construction of Opa-positive and Opa-negative strains of Neisseria meningitidis to evaluate a novel meningococcal vaccine.Cysteine depletion causes oxidative stress and triggers outer membrane vesicle release by Neisseria meningitidis; implications for vaccine developmentBordetella pertussis naturally occurring isolates with altered lipooligosaccharide structure fail to fully mature human dendritic cellsThe Omp85 protein of Neisseria meningitidis is required for lipid export to the outer membraneExpression of the lipopolysaccharide-modifying enzymes PagP and PagL modulates the endotoxic activity of Bordetella pertussis.Acellular pertussis vaccine based on outer membrane vesicles capable of conferring both long-lasting immunity and protection against different strain genotypes.Lipopolysaccharide analogs improve efficacy of acellular pertussis vaccine and reduce type I hypersensitivity in mice.Agonists of Toll-like receptors 3, 4, 7, and 9 are candidates for use as adjuvants in an outer membrane vaccine against Neisseria meningitidis serogroup B.Relative immunogenicity of PorA subtypes in a multivalent Neisseria meningitidis vaccine is not dependent on presentation form.Antigen sparing with adjuvanted inactivated polio vaccine based on Sabin strainsIdentification of a novel lipopolysaccharide core biosynthesis gene cluster in Bordetella pertussis, and influence of core structure and lipid A glucosamine substitution on endotoxic activity.Meningococcal Outer Membrane Vesicle Composition-Dependent Activation of the Innate Immune Response.TLR4-dependent adjuvant activity of Neisseria meningitidis lipid AOpa+ and Opa- isolates of Neisseria meningitidis and Neisseria gonorrhoeae induce sustained proliferative responses in human CD4+ T cells.Lipopolysaccharide engineering in Neisseria meningitidis: structural analysis of different pentaacyl lipid A mutants and comparison of their modified agonist properties.Human dendritic cell activation by Neisseria meningitidis: phagocytosis depends on expression of lipooligosaccharide (LOS) by the bacteria and is required for optimal cytokine production.Biosynthetically engineered lipopolysaccharide as vaccine adjuvant.Llama single-chain antibody that blocks lipopolysaccharide binding and signaling: prospects for therapeutic applications.Phase variation of Opa proteins of Neisseria meningitidis and the effects of bacterial transformation.Supplementation of whole-cell pertussis vaccines with lipopolysaccharide analogs: modification of vaccine-induced immune responses.Differential activation of human and mouse Toll-like receptor 4 by the adjuvant candidate LpxL1 of Neisseria meningitidis.Th17-mediated cross protection against pneumococcal carriage by vaccination with a variable antigen.Modulating endotoxin activity by combinatorial bioengineering of meningococcal lipopolysaccharide.Teasing apart structural determinants of 'toxicity' and 'adjuvanticity': implications for meningococcal vaccine development.Involvement of lipooligosaccharides of Haemophilus influenzae and Neisseria meningitidis in defensin-enhanced bacterial adherence to epithelial cells.Surface display of a borrelial lipoprotein on meningococcal outer membrane vesicles.Modulation of the CD4(+) T cell response after acellular pertussis vaccination in the presence of TLR4 ligation.Working mechanism of immunoglobulin A1 (IgA1) protease: cleavage of IgA1 antibody to Neisseria meningitidis PorA requires de novo synthesis of IgA1 Protease.Meningitis caused by a lipopolysaccharide deficient Neisseria meningitidis.Lipoarabinomannan mannose caps do not affect mycobacterial virulence or the induction of protective immunity in experimental animal models of infection and have minimal impact on in vitro inflammatory responses.A novel secondary acyl chain in the lipopolysaccharide of Bordetella pertussis required for efficient infection of human macrophages.
P50
Q26766539-FEA4BFFC-EC68-4EBF-A1CC-115F299C3B49Q28475336-BC4B210B-F047-4FA9-8331-8D296FE64CF6Q28493076-428C1E54-8735-436C-9D01-98F7E49F40E4Q28493123-01E883DA-D063-485E-B180-97BB36B8D3AEQ33768763-CE994A4D-6D12-4257-8110-EA9E54AB16A6Q33784386-31920867-61DC-402F-88EC-78050389248CQ33963083-31EAA838-278E-453F-A98B-E2A36D2D84DEQ34376049-40B48DC6-F80D-47F7-B5B5-06B9EEDC0F6CQ34499619-DF3655DA-95FA-4077-A92F-34A1DD9547A7Q34516060-F8E9C084-9BED-41C9-9AE0-08A39F788DB3Q34571107-5A7E1466-8B7B-46C2-8778-05ED07778118Q34889754-633A2118-776F-4771-B8A2-6296C706F0F1Q34985648-FDF818EA-FD47-4E19-B23A-34FFB93E9B79Q35073933-B67EB542-7E83-452D-AA22-35597F33D4C7Q35084516-9E167E1C-DF82-4C38-8DA1-83C1A4D88E84Q35946895-63304E3A-77CF-4F97-A956-1622A24B3857Q36313996-A22EF933-8B37-41A0-8C66-92D9B0406EC8Q36375593-0D14E753-ABC8-4A12-A0AE-D97F6E31D855Q36605148-57105731-0BB8-4F5D-9D89-AD775CF8D33BQ37256450-CD59CF41-381E-486B-A3A8-3151AAA7B25EQ37287207-4AEADFA7-524A-45E1-834D-3D67060818CAQ37292481-6E5A0316-19A5-4C58-B78D-67D9E7A67414Q37410366-794D096B-915D-409D-A7FC-3B3AA6F86D92Q37653359-0C715BA6-96EC-4FDB-8135-DA42BA16A844Q38340295-CA763D75-1808-4024-B222-BF0335FE8AE4Q38386726-AF3E9BBF-EE7E-489F-8FC3-130AE484DE21Q38499088-590E48FB-7B51-4CB6-AE47-52E6A1FCF3C6Q39418716-62E661E4-2CD7-4DB9-BC83-2CA556006074Q40022559-C0CE8384-58B5-429E-8019-5A9E49040ED2Q40090049-E7ADA1B2-095E-4E42-B450-67266736C906Q40119286-C1F34D98-361D-4E34-B4CC-158A6F429695Q40453387-A499E401-73BA-412B-86B3-2DC80B007250Q40513524-AECACEB2-EDF7-4B3F-9261-8734DF497C1AQ40664749-5F445D1D-B7D2-4120-8A81-4313E21453B5Q40821392-04808DAC-7BC4-4E63-AA01-95151C7F71E8Q41497441-1E0F403E-920F-46E0-A434-A87873FDB262Q41971192-A248BE6D-0248-4FA1-ACFD-40490624CF61Q42210345-3F74A3AA-BC8E-44E8-969D-C2E448AAE2E9Q43546947-6AD776CB-DAC1-431D-8F34-559170009F18Q44086051-53936A0F-CFC6-4B3D-B99E-F829A9F9633D
P50
name
Peter van der Ley
@ast
Peter van der Ley
@en
Peter van der Ley
@es
Peter van der Ley
@nl
type
label
Peter van der Ley
@ast
Peter van der Ley
@en
Peter van der Ley
@es
Peter van der Ley
@nl
prefLabel
Peter van der Ley
@ast
Peter van der Ley
@en
Peter van der Ley
@es
Peter van der Ley
@nl